RT Journal Article
SR Electronic
T1 Once-daily QVA149 improves symptom scores in patients with COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3637
VO 42
IS Suppl 57
A1 Tobias Welte
A1 Ronald Dahl
A1 Hungta Chen
A1 Nicola Gallagher
A1 Peter D'Andrea
A1 Vijay Alagappan
A1 Donald Banerji
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P3637.abstract
AB IntroductionQVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium in development for the treatment of COPD. Here we present the symptom score results from three Phase III studies of QVA149.MethodsAll three studies were multicenter, double-blind, parallel-group, which randomized patients (pts) ≥40 yrs with moderate-to-severe COPD. E-diaries were provided to pts to record their daily symptoms.ResultsThe SHINE, ENLIGHTEN and ILLUMINATE studies randomized 2144, 523 and 339 pts, respectively. QVA149 patients had statistically significant improvements in symptom scores compared with other treatment groups as shown in table.View this table:Table: Mean treatment difference in symptom scoresConclusionOnce-daily QVA149 provides improvements in COPD symptoms compared to indacaterol, glycopyrronium, tiotropium and salmeterol/fluticasone.